IV to PO Hydralazine Dose Conversion
There is no established IV-to-PO dose conversion for hydralazine because NAT2 polymorphic acetylation affects oral but not intravenous pharmacokinetics, making direct dose equivalency impossible. 1
Why Direct Conversion Doesn't Exist
The fundamental pharmacokinetic difference between routes makes conversion problematic:
- IV hydralazine bypasses first-pass metabolism entirely - no acetylation occurs before reaching systemic circulation 1
- Oral hydralazine undergoes extensive first-pass hepatic metabolism via NAT2 acetylation, with bioavailability ranging from only 26-55% in healthy subjects 2 and as low as 9.9% in rapid acetylators with heart failure 3
- Oral bioavailability varies dramatically based on NAT2 genotype (poor metabolizers have 2-3 times higher bioavailability than rapid metabolizers) 3
Practical Clinical Approach
Transitioning from IV to Oral Therapy
When converting from IV to oral hydralazine (which should occur within 24-48 hours per FDA labeling 4):
Start with standard oral dosing regimens rather than attempting mathematical conversion:
- Initial oral dose: 40-75 mg total daily (divided into 2-4 doses) 1
- For a patient previously on IV hydralazine 20-40 mg as needed, begin with 25 mg PO three to four times daily (total 75-100 mg/day)
- Titrate based on blood pressure response, not the IV dose used
Key Dosing Parameters
FDA-approved oral dosing range: 4, 5
- Minimum: 40 mg/day (10 mg four times daily)
- Maximum: 300 mg/day (100 mg three times daily)
- American Heart Association recommends limiting to 200 mg/day maximum to reduce drug-induced lupus risk 1
Standard IV dosing: 4
- 20-40 mg per dose, repeated as necessary
- Used only when oral administration impossible
- Maximal BP decrease occurs 10-80 minutes post-injection
Critical Caveats
Route-Dependent Metabolism
Research demonstrates that oral administration produces relatively more of the acetylated metabolite MTP compared to IV administration (0.8-1.2% vs 1.4-2.3% urinary recovery), confirming route-dependent first-pass metabolism 2. This means the same milligram dose produces vastly different systemic drug exposure depending on route.
Dose-Dependent Bioavailability
At higher oral doses (225-3000 mg/day), bioavailability increases disproportionately due to saturation of first-pass metabolism 3. This nonlinear pharmacokinetics further complicates any conversion attempt.
Safety Considerations
- IV hydralazine produces the most significant BP reduction among commonly used antihypertensives for severe inpatient hypertension (13 mmHg MAP reduction) 6
- Risk of hypotension, acute kidney injury, and ICU transfers when IV agents used inappropriately for asymptomatic BP elevations 7, 8
- Drug-induced lupus risk increases with cumulative exposure, particularly at doses ≥200 mg/day 1
Bottom Line
Rather than converting 25 mg PO to an IV equivalent, use standard IV dosing (20-40 mg) when IV route is necessary, and use standard oral starting doses (40-75 mg/day) when transitioning to oral therapy. Titrate each route independently based on clinical response, recognizing these are fundamentally different pharmacokinetic scenarios that cannot be mathematically equated.